CG Oncology Inc（CGON）財務資料CGONCG Oncology Inc

Evaluating the bottom line, CG Oncology, Inc. maintains a gross margin of -239.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7467.68%, while the net margin is -6832.84%. These profitability ratios, combined with a Return on Equity (ROE) of -26.41%, provide a clear picture of how effectively CGON converts its operational activities into shareholder value.

In the context of the broader market, CGON competes directly with industry leaders such as KOD and COGT. With a market capitalization of $5.66B, it holds a significant position in the sector. When comparing efficiency, CGON's gross margin of -239.24% stands against KOD's N/A and COGT's N/A. Such benchmarking helps identify whether CG Oncology, Inc. is trading at a premium or discount relative to its financial performance.

CG Oncology reported a Q2 2026 net income of -$79,056,000 and an EPS of -$0.90, reflecting ongoing financial challenges. The gross margin has significantly declined to -239.24% in Q2 2026, indicating issues in profitability.